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The management of chronic inflammatory diseases, such as inflammatory bowel dis-
ease, psoriasis, and rheumatoid arthritis has significantly improved over the last decade 
with the clinical availability of anti-TNF-α biologics. Despite this undoubted treatment 
success, a combination of acquired resistance together with an increased risk of sys-
temic complications, means that a significant number of patients either fail to find a 
suitable targeted therapy or frustratingly discover that an approach that did work is no 
longer efficacious. Here, we report the isolation and characterization of a new class of 
super-neutralizing anti-TNF-α biologics formats, the building blocks of which were origi-
nally derived as variable new antigen receptor (VNAR) domains from an immunized nurse 
shark. These parental small, stable VNAR monomers recognize and neutralize tumor 
necrosis factor (TNF)-α, in cell-based assays, at nanomolar concentrations. However, 
the simple, single-chain molecular architecture of VNARs allows for easy and multiple 
reformatting options. Through reformatting, we achieved a 50,000-fold enhancement 
in in vitro efficacy with super-neutralizing fusion proteins able to block TNF-α induced 
cytotoxicity in the 2–5 pM range while retaining other functionality through the addition 
of fusion proteins known to extend serum half-life in vivo. In an in vitro intestinal epithelial 
barrier dysfunction efficacy model, the lead VNAR domains, restored barrier function and 
prevented paracellular flux with comparable efficacy to adalimumab (Humira®). In addi-
tion, all multivalent VNAR constructs restored trans-epithelial electrical resistance (TEER) 
to approximately 94% of the untreated control. Reformatted VNAR domains should 
be considered as a new class of biologic agents for the treatment of hTNF-α driven 
diseases; either used systemically with appropriate half-life extension or alternatively 
where site-specific delivery of small and stable neutralizers may provide improvements 
to current therapy options.
Keywords: variable new antigen receptor, tumor necrosis factor-α, phage display, cytokine neutralization, chronic 
inflammation, shark ignar, bi-paratopic/bi-specific binding domain, anti-TnF biologics
Abbreviations: VNAR, variable new antigen receptor; TEER, trans-epithelial electrical resistance; hTNF-α, human tumor 
necrosis factor-alpha; IBD, inflammatory bowel disease; RA, rheumatoid arthritis; IL, interleukin; IgNAR, immunoglobulin 
new antigen receptor.
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inTrODUcTiOn
Tumor necrosis factor (TNF) alpha is an important cytokine 
produced by macrophages and a key component of the host’s 
defenses. TNF is released rapidly following all types of trauma 
and stimuli; however, excessive or persistent production often 
results in immunopathology, including autoimmune disease 
and debilitating inflammation (1, 2). It is now well established 
clinically that targeted neutralization of human (h)TNF-α, 
or blockade of the receptor mediated signaling pathway, can 
result in disease control and/or remission (3, 4) with a number 
of approved antibody-based biologics targeting either TNF-α, 
or their corresponding receptors in the clinic (3, 5–7). In fact, 
anti-TNF-α biologic approaches have, for a number of years, been 
the most commercially lucrative area of disease treatment for 
many pharmaceutical companies with the anti-TNF-α antibody 
adalimumab (Humira®) selling over $10 B every year since 2014 
(2, 8, 9). Despite this success there still remain significant gaps 
in the available panel of anti-TNF therapies. From the very first 
use of anti-TNF-α biologics, clinicians have reported patient 
cases of non-responders or patients that become suddenly recal-
citrant to first one and then subsequent anti-TNF-α biologics. 
Most cases of therapeutic failure are linked to the development 
of neutralizing anti-drug antibodies (ADA) with molecular 
structure, posttranslational modifications, route and frequency 
of administration, and duration of treatment largely associated 
with the development of ADAs and treatment withdrawal (10, 
11). Furthermore, there is a growing body of evidence warning 
against the long-term exposure to systemic anti-TNF-α therapy. 
It appears to increase the risk of some patients developing sec-
ondary and life-threatening infections and malignancies (12–14). 
Therefore, there remains a need for new anti-TNF-α modalities 
and for new anti-TNF-α biologic formats that may avoid or at 
least, limit these risks. Extending therapy options for the growing 
number of patients who have exhausted current biologic-based 
anti-TNF-α control is also another desirable.
At approximately 11  kDa, variable new antigen receptor 
(VNAR) domains are the smallest naturally occurring independ-
ent binding domains in the vertebrate kingdom (15–21). The 
characteristic protruding paratopes, of VNARs means that they 
are often referred to as “canyon-binders,” pre-disposed to insert-
ing themselves into pockets or grooves in proteins, resulting in an 
increased selection propensity of potent neutralizers of receptors 
and/or enzymes (22–24).
Their simple, single-domain architecture makes reformat-
ting of these domains relatively straightforward with VNARs 
amenable to both N- and C- terminal molecular fusions without 
loss of function (21, 25–27). Here, we demonstrate that a range 
of additional functionalities can be added that go beyond target 
specificity and include: quadra-valency, bi-valent-bi-specificity, 
serum half-life extension, or immune system recruitment (or all 
four together) and that this multifunctionality can be achieved 
using a single fusion protein of around 50  kDa or less. While 
“systemic-friendly” formulations can be readily cloned and 
expressed, we have also shown that smaller, bi-valent, bi-specific, 
or even bi-paratopic formats of around 25 kDa, can be expressed 
cost-efficiently and at scale in non-mammalian systems. These 
highly stable formats (28–30) retain the neutralizing potency of 
their larger cousins, but are ideally suited to novel site-specific or 
topical administration thus minimizing the risk of the systemic 
side-effects often associated with parenteral administration of, for 
example, anti-TNF-α biologics.
In this particular study, we have isolated two anti-hTNF-α neu-
tralizing VNARs through shark immunization and phage display 
and reformatted these domains as multifunctional, multivalent 
constructs. These fusion proteins retained their inherent binding 
specificity and stability while delivering improved binding affin-
ity and super-neutralizing anti-hTNF-α potency.
MaTerials anD MeThODs
shark immunization
Nurse sharks (Ginglymostoma cirratum) were immunized with 
recombinant hTNF-α (200  μg)/shark emulsified in complete 
Freund’s adjuvant as described by Kovaleva et  al. (31). Four 
weeks later, 200  µg hTNF-α/shark emulsified in incomplete 
Freund’s adjuvant was administered. Two immunization boosts 
at concentrations of 100 µg hTNF-α/shark and a final boost of 
50 µg hTNF-α/shark were given at 4-week intervals intravenously 
into the caudal vein as soluble antigen in phosphate buffered 
saline (PBS) (sample 0.45  µM sterile filtered). Blood samples 
were collected at weeks 0 (pre-immunization bleed), 10, 14, and 
18. Peripheral blood lymphocytes (PBLs) isolated and total RNA 
prepared.
Detection of hTnF-α specific ignar in 
shark serum
IgNAR titer in the bleeds was measured using hTNF-α-coated 
ELISA plate. Detection was carried out using the IgNAR-specific 
monoclonal antibody (GA8) at a dilution of 1:200 in PBS, pH 7.4; 
see Müller et al. (26) for a detailed protocol.
Total rna isolation from PBls and 
immune Phage library construction
Peripheral blood lymphocytes were harvested from the plasma 
of the bleed with the best IgNAR response (Bleed 5) and total 
RNA prepared. Total RNA from the harvested PBLs was used 
at approximately 2 µg/µl as template for cDNA synthesis using 
Superscript III First strand synthesis supermix (Invitrogen). cDNA 
was generated with the framework specific primers NARF4For1 
(5′-ATA ATC AAG CTT GCG GCC GCA TTC ACA GTC ACG 
ACA GTG CCA CCT C-3′) and NARF4For2 (5′-ATA ATC 
AAG CTT GCG GCC GCA TTC ACA GTC ACG GCA GTG 
CCA TCT C-3′) (16). Following cDNA synthesis, the common 
framework one specific primer NARF1Rev (5′-ATA ATA AGG 
AAT TCC ATG GCT CGA GTG GAC CAA ACA CCG-3′) was 
introduced and IgNAR V (VNAR) region DNA amplified using 
a 3-step PCR amplification protocol. The resultant PCR product 
of approximately 400 base pairs was run on 1.5% agarose gel, and 
VNAR region cut out and purified (QIAquick purification kit, 
QIAGEN). Purified DNA was digested at the primer-encoded 
restriction sites (underlined) with the restriction enzymes NcoI 
and NotI (NEB), and re-purified. The VNAR restriction-enzyme 
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digested DNA library was cloned into a pHEN2 phagemid vector 
(32), and transformed into a suitable E. coli strain.
Phage Display selection and screening
A single aliquot of library stock equivalent to OD600 of 0.1 was 
added to 2× TY growth media containing 2% glucose (w/v), 
100  µg/ml ampicillin, and grown at 37°C to mid-log phase 
(OD600 of 0.4–0.6) prior to infection with M13K07 helper phage 
(NEB). Library expression was conducted overnight in 2× TY 
media, 100 µg/ml ampicillin, and 50 µg/ml kanamycin at 30°C. 
Phage were PEG-precipitated from the culture supernatant and 
used for bio-panning. The library was panned against bioti-
nylated rhTNF-α captured on streptavidin beads (Dynabeads, 
Invitrogen). Library phage and Dynabeads M-280 streptavidin 
were pre-blocked with block solution [3% (w/v) milk, 1% (w/v) 
BSA in PBS] for 1  h, rotating at room temperature. Biotin-
rhTNF-α (400 nM) was added to blocked beads and incubated 
for 1  h, rotating at room temperature. Phage were deselected 
by incubating with blocked beads, 1  h rotating at room tem-
perature. Biotin-rhTNF-α decorated beads were incubated with 
deselected phage for 1 h, rotating at room temperature. Beads 
were washed 5× PBST and 5× PBS prior to a strict 8-min elu-
tion with 400 µl of 100 mM Triethylamine, and neutralized by 
adding 200 µl of 1 M Tris–HCl pH 7.5. Mid-log phase E. coli 
TG1 cells (10  ml) were infected with 400  µl eluted phage for 
30 min, at 37°C. Then, grown overnight at 37°C on TYE agar 
plates containing 2% glucose (w/v), 100 µg/ml ampicillin. Three 
further rounds of selection were conducted and stringency was 
increased in round 3 and 4 by reducing the concentration of 
biotin-rhTNF-α to 200  nM. Enrichment of antigen binding 
monoclonal phage was evaluated using hTNF-α-coated ELISA 
plates.
Vnar Binding elisa
Ninety-six well flat bottom Maxisorp Nunc Immuo plates 
(Thermo Scientific) were coated with antigen of interest [1 µg/
ml hTNF-α, BSA, human serum albumin (HSA), etc.] for 1 h at 
37°C or 4°C overnight. The plates were washed three times with 
200 µl/well PBST [PBS with 0.1% (v/v) Tween 20] before blocking 
with 200 µl of 4% m (w/v) PBS (MPBS) per well and incubated 
at 37°C for 1 h. The blocked plates were washed three times with 
PBST, and 100 µl of VNAR protein solution was added per des-
ignated well and plates were incubated at room temperature for 
1 h. Plates were washed three times with PBST and 100 µl of 1 in 
1,000 dilution HRP conjugated anti-c-myc, anti-poly-histidine, 
or goat anti-human IgG antibody was added to the plates and 
incubated for 1 h at room temperature. The plates were washed 
and developed by adding 100 µl tetramethylbenzidine substrate 
solution and neutralized using 50 µl 1 M H2SO4.
Determination of anti-hTnF-α Vnar 
specificity
Binding specificity was determined on ELISA plates coated with 
either 1 µg/ml biotin-hTNF-α or unbiotinylated hTNF-α, 10 µg/
ml HSA, BSA, streptavidin, single stranded DNA, thyroglobulin, 
or lysozyme. ELISA plates were suitably blocked in 4% (w/v) 
Milk-PBS, and VNAR protein samples loaded at a top concentra-
tion of 1 µg/ml and a two-fold dilution series performed. Binding 
was detected with an anti-c-myc-HRP conjugated monoclonal 
antibody.
construction of Multivalent Bi-Paratopic/
Bivalent Vnar Domains
For this purpose, total DNA was isolated from single clones har-
boring VNAR fragments of interest. Oligonucleotides required 
for this formatting were designed in-house, and produced by 
Sigma-Aldrich, UK. VNAR fragments were PCR amplified with 
corresponding oligonucleotide pair, thereby introducing desired 
restriction sites and a flexible linker (Gly4Ser)n. For dimer con-
structs, two VNAR fragments PCR formatted with unique clon-
ing sites were cloned into pET28b (+) plasmid vector in two steps 
via their unique restriction sites.
For the trimeric construct, a GeneArt Gene Synthesis plas-
mid containing a custom-made plug-and-play DNA fragment 
with VNAR BA11 (a humanized anti-HSA) fragment located at 
base position 436–744 and flanked by both N- and C- terminal 
(Gly4Ser)4 flexible linkers, and cloning sites at positions 52–363 
(XbaI/BamHI) and 817–1125 (ApaI/EcoRI) for the insertion of 
anti-TNF VNAR fragments was utilized. Complete anti-TNF 
VNAR trimeric construct DNA ligated into pET28b(+) via 
XbaI and EcoRI restriction sites, followed by transformation into 
electrocompetent SHuffle® T7 Express cells.
Single E. coli clones were picked and grown in terrific broth 
containing the selection antibiotic.
The Quad™ constructs were designed in-house and the gene 
made by GeneArt Gene Synthesis (Thermo Fisher Scientific) 
incorporating cloning sites BssHII and EcoRI. All Quad™ con-
structs were designed to incorporate a GlySer-rich short linker 
before linking to the hinge of a wild-type human IgG1. Specific 
to the Quad-X™, a (Gly4Ser)4 flexible was incorporated at the end 
of CH-3 and a VNAR fused to the flexible linker.
soluble Vnar Protein expression and 
Purification
Soluble VNAR protein was expressed in both prokaryotic (E. coli) 
and eukaryotic systems (P. pastoris, HEK293, and CHO K1 cells). 
Expression in E. coli HB2151 cells was induced with 1 mM iso-
propyl β-d-1-thiogalactopyranoside (IPTG), and soluble VNAR 
protein was extracted from the periplasm (E. coli HB2151 cells) 
(31). All multivalent non-Fc VNAR constructs were expressed as 
cytoplasmic protein in IPTG-induced E. coli SHuffle® T7 Express 
cells (NEB) using pET28b(+) expression vector. Extraction of 
cytoplasmic VNAR protein was achieved using the BugBuster™ 
protein extraction reagent plus Benzonase® (Novagen).
Polyethylenimine-mediated transfection and transient expres-
sion in HEK293 host cells was performed using serum-free 
FreeStyle™ 293 media (Invitrogen) (31, 33–36). The Quad-X™ 
construct was also efficiently expressed in suspension-adapted 
CHO K1 cells by Evitria AG, Zurich, Switzerland (www.evitria.
com), using an Evitria expression vector system. The cell-seed 
was grown in eviGrow medium, a chemically defined, animal-
component free, serum-free medium. Cells were transfected with 
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eviFect, Evitria’s custom-made, proprietary transfection reagent, 
and cells grown after transfection in eviMake2, an animal-
component free, serum-free medium.
Heterologous expression of multivalent VNAR constructs in 
P. pastoris was performed by Novoprotein Scientific Inc., USA, 
essentially as described by Weidner et al. (36).
All VNAR constructs were purified via poly-histidine tag using 
immobilized metal affinity chromatography, while Protein-A 
affinity chromatography was adopted for the VNAR-Fc purifica-
tion. VNAR protein eluted from affinity columns was dialyzed 
against PBS, pH 7.4. Electrophoresis of purified protein samples 
was performed on NuPAGE 4–12% Bis-Tris gels using a MES 
buffer system (Invitrogen) in accordance with the manufacturer’s 
instructions. Expression levels ranged from about 10 mg/l (non-
Fc-based VNAR constructs) in E. coli systems to up to 150 mg/l 
(Fc-based VNAR constructs) in mammalian systems.
Vnar affinity Determination
Octet FortéBio® Biolayer interferometry (BLI) was used to 
determine the equilibrium dissociation constant (KD). Dip and 
Read™ streptavidin biosensors loaded with biotinylated hTNF-α 
and anti-TNF-α VNAR proteins were diluted using a twofold 
dilution series with top concentration of 100 nM while VNAR 
negative controls were assayed at top concentrations of 100 nM 
and 1 µM. Binding association was monitored for 10 min followed 
by a 5 min dissociation time. The biosensor was regenerated with 
2 × 300 s washes in high salt buffer, TBST (10 mM Tris, 140 mM 
NaCl, 0.01% Tween 20, pH 7.4).
In addition to the Octet affinity data, a single cycle kinetics 
screen of the VNAR constructs was also conducted using surface 
plasmon resonance in a BIAcore™ T200 instrument. In summary, 
hTNF-α was covalently bound to a CM5 sensor chip surface via 
amine coupling until an increase of around 200 response units was 
reached. Start-up cycles were composed of a 60-s buffer injection 
at a flow rate of 30 µl/min followed by a 30-s dissociation period. 
Anti-hTNF-α VNAR cycles consisted of a 120-s sample injection 
at 30 µl/min, with a 1,200-s dissociation time. A regeneration step 
of a 60-s injection of 10 mM glycine buffer, pH 2.0 at 30 µl/ml, 
followed by a 120-s stabilization period was incorporated at the 
end of each cycle.
ph stability assessment
Variable new antigen receptor protein samples were prepared 
and incubated at a working concentration of 10 µg/ml in a final 
volume of 50 µl at designated pH value. Incubation pH 3.0 was 
titrated using 1 M HCl or 0.1 M citric acid against PBS, pH 7.4. 
VNAR protein samples were incubated at pH 3 for 28 days, at 
room temperature. Samples withdrawn at stipulated time points 
were immediately neutralized in 10× PBS, pH 7.4 to a final con-
centration of 0.5  µg/ml. Neutralized samples were assessed for 
activity retention using hTNF-α-coated ELISA plates.
In Vitro hTnF-α neutralization assay in 
l929 cells
The TNF-α sensitive mouse fibrosarcoma cell line (L929 cells) 
were grown to 90% confluence, seeded onto 96-well flat bottom 
microtiter cell culture plate at 5,000 cells per well, and incubated 
for 48 h. Cells were treated with 1 µg/ml actinomycin-D, before 
adding a 20 min co-incubated 0.3 ng/ml (1× LD80 dose) hTNF-α 
and anti-hTNF-α VNAR proteins (this step of co-incubation is 
not crucial as TNF-α can be added directed to wells containing 
cells, anti-TNF-α VNAR and actinomycin-D). Treated cells were 
incubated for 24  h at 37°C with 5% (v/v) CO2 and humidity. 
Cytotoxicity or cell survival was determined by adding tetrazo-
lium salt (WST-1) cell proliferation reagent (Roche), and incu-
bated for a further 24 h. Absorbance was read at 450 nm using a 
microplate reader.
FiTc-Dextran Paracellular Flux across 
Polarized Monolayer of caco-2 cells
Human epithelial colorectal adenocarcinoma cells (Caco-2) were 
grown to 90% confluence before seeding onto 24 wells, 0.4 µm 
semi-permeable tissue culture transwell inserts (Corning Inc.) at 
5,000 cells per transwell insert in a final volume of 100 µl, with 
600  µl complete DMEM without cells was transferred into the 
outer containing wells. Transwell plates were incubated at 37°C 
with 5% (v/v) CO2, and humidity, and spent DMEM  +  10% 
(v/v) FBS replaced every 48 h. Cell proliferation was monitored 
under a phase contrast microscope (40× magnification objec-
tive) until cells attain 100% confluence, usually between 5 and 
7  days post-seeding. Cells were grown for a further 21  days 
allowing differentiation, with spent medium changed every 48 h 
until differentiation. Designated insert wells were treated with 
10 ng/ml hTNF-α, IFN-γ, and LPS with or without anti-hTNF-α 
VNAR proteins. Treated cells were incubated for 18  h at 37°C 
with 5% (v/v) CO2, and humidity. Following incubation for 18 h 
with cytokines ± anti-TNF-α VNARs, phase contrast images of 
treated cells were captured followed by the addition of 5  µl of 
10 mg/ml fluorescein isothiocyanate-labeled dextran, molecular 
weight (3–5  kDa) to the apical side (insert wells) of Caco-2 
monolayer. Medium from the basolateral side of the transwell 
chamber was collected at 2 and 24  h after addition of FITC-
dextran. Fluorescence intensity was measured using a Synergy 
HT (BioTek®) microplate reader at 485 nm excitation and 520 nm 
emission wavelengths (37, 38).
epithelial resistance Dysfunction assay in 
Polarized caco-2 cell Monolayer
The protocol described for FITC-Dextran paracellular flux across 
polarized monolayer of Caco-2 cells was followed until designated 
cells were treated with 10 ng/ml hTNF-α, IFN-γ and LPS with 
or without anti-TNF-α VNAR proteins. Following incubation 
for 24 h with cytokines ± anti-hTNF-α VNAR domains, trans-
epithelial electrical resistance (TEER) was measured in the apical 
chamber using Millicell® ERS-2 Epithelial (Volt/Ohm) meter and 
MERSSTX01 electrode (Merck Millipore). Measured resistance 
values were normalized to the surface area under treatment.
It is important to note that 12-well tissue culture transwell 
inserts were seeded with 5  ×  106 cells/well containing 500  µl 
DMEM with outer well (basolateral side) containing 1.5  ml 
DMEM. Also during TEER measurement, DMEM volume in 
the insert wells was increased to 500 µl to allow volt-ohm meter 
electrodes to fully submerge in the medium without touching the 
base of the wells (37, 38).
TaBle 2 | Neutralization of 0.3 ng/ml (LD80) hTNF-α-induced cytotoxicity in L929 
cells.













D1–C4–Fc (Quad-Y™) 0.005 ± 0.001 (n = 2 ± SD)
C4–D1–Fc (Quad-Y™) 0.012 ± 0.002 (n = 2 ± SD)
TaBle 1 | Binding kinetics of anti-hTNF-α variable new antigen receptor using 
Octet® RED96 system.
Binding domain Kon (M−1s−1) Koff (s−1) KD (nM) KD (nM) Biacore
D1 3.6 × 105 1.7 × 10−2 n/a 47.5
C4 1.1 × 106 8.0 × 10−2 n/a 73.5
TNF30 8.2 × 104 1.4 × 10−3 n/a 16.7
D1–D1 5.0 × 105 3.2 × 10−4 0.6 n/a
D1–C4 1.8 × 105 1.1 × 10−4 0.6 5.0
D1–BA11–D1 1.9 × 106 2.0 × 10−4 0.1 4.0
D1–BA11–C4 1.8 × 105 4.8 × 10−5 0.3 0.6
For all measurements, streptavidin Dip and Read™ biosensors were used to immobilize 
biotinylated hTNF-α. All assessed domains were loaded at a top concentration of 
100 nM followed by a twofold dilution series. Values obtained from BIAcore binding 
analysis are shown in italics, and constructs not tested are shown as “not available” 
(n/a).
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statistical analysis
Graph Pad Prism®, version 5.04 was used to perform statistical 
analysis on experiments with a minimum of three (3) independ-
ent repeat experiments with duplicates/experiment. All values 
shown are means of n = 3 experiments ± SEM (unless otherwise 
stated).
resUlTs
immunized Phage library construction
An antigen-driven IgNAR immune response was determined 
post immunization by measuring the IgNAR titer in the sera (pre- 
and post-bleeds, respectively). An increase in hTNF-α specific 
IgNAR was observed following each successive immunization 
boost up to and including the final boost. Unlike the antibody 
titers seen for a mouse or rabbit immunization which could be up 
to 100,000, the IgNAR titers appears much more slowly than an 
any antibody response and peaked here after five boosts at around 
1,000 (results not shown).
The VNAR repertoire was PCR amplified from isolated PBLs 
and cloned into a phagemid vector containing an in-frame M13 
bacteriophage truncated coat protein pIII gene. Library quality 
control including PCR amplification of insert frequency and 
DNA sequencing of the IgNAR V regions of a representative 
sample (randomly selected 300 clones) was performed. This 
analysis confirmed that 85% of the library incorporated a VNAR 
sequence, and that 79% of the library encoded functional inserts, 
each possessing a unique amino acid sequence in the CDR3 (data 
not shown). The corrected library size generated was estimated at 
8.7 × 108 transformants.
isolation of anti-hTnF-α-specific Vnars
Variable new antigen receptor domains specific for hTNF-α were 
isolated following four rounds of selection against biotinylated 
hTNF-α captured on streptavidin beads. Unlike solid-surface 
immobilized antigen, this approach presents the target in a “solu-
tion state” thereby allowing access to the antigen’s entire surface, 
thus maximizing the chance of isolating specific and high-affinity 
anti-hTNF-α VNAR. Stringency was introduced in the third 
and fourth rounds of selection by reducing the concentration 
of antigen by half. As specific binding to hTNF-α was our key 
anticipated outcome, randomly selected output monoclonal 
phage from each selection were screened for binding to target 
antigen and unrelated non-target protein (HSA and streptavidin). 
A steady increase in antigen binding was observed from pre-
selected clones through to round 2 (100% positive), with a drop 
in the number of monoclonal phage binders after round 3 (75%) 
and 4 (80%). No binding to unrelated non-target proteins was 
observed.
characterization of anti-hTnF-α Vnars 
as Monomers
From an original panel of 24 unique (by DNA sequence) anti-
hTNF-α binding clones, two VNAR domains D1 and C4 were 
eventually selected as leads following a series of assays that 
considered binding affinity, efficacy in cell-based bio-assays 
and expressibility in E. coli. The expression yield of these two 
monomeric domains ranged from 7 to 14 mg/l in SHuffle® cells. 
To benchmark the performance of the VNAR leads, a single-
domain anti-hTNF-α VHH TNF30 (39, 40) was included as an 
appropriate positive control. As monomers, VNARs D1 and C4 
recorded a binding affinity (KD) of 47 and 73 nM (Table 1), and 
neutralized hTNF-α-induced cytotoxicity in L929 cells at 30 and 
100 nM, respectively (Table 2).
reformatting Vnar Monomers as 
Multivalent constructs
To exploit the ease with which VNARs can accommodate 
molecular reformatting and in an effort to significantly enhance 
their activity (binding affinity, avidity, and efficacy), VNARs 
D1 and C4 were fused via a flexible GlySer linker to form 
homo-and hetero-dimers, with a number of possible dimer 
outcomes (D1–D1, D1–C4, C4–C4, and C4–D1). These dimer 
constructs were further screened for neutralization efficacy and 
expressibility in E. coli. VNARs D1–C4 and D1–D1 showed 
significantly improved neutralizing potencies while expression 
yields remained almost unaffected (Table 2; Figure 1). In con-
trast, dimer constructs with VNAR C4 as the N-terminal fusion 
partner resulted in poor expression yields (less than 1 mg/l) and 
FigUre 1 | SDS PAGE and protein expression yield analysis of variable new antigen receptor (VNAR) constructs. (a) SDS PAGE and Coomassie blue staining of 
5 µg of dithiothreitol-treated VNAR constructs. M, molecular weight marker. (B) Protein expression yield in specified expression systems. All expression were 
conducted in at least 1 l culture volume, except D1–Fc (* refers to a 200-ml culture volume).
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minimal efficacy improvement (data not shown). In trivalent 
formats, where the spacing between the functional anti-TNF-α 
binding domains was increased further (Figure 2) through the 
inclusion of a well-characterized anti-HSA binding soloMER™ 
(humanized VNAR) domain BA11 (41), trimers D1–BA11–D1 
and D1–BA11–C4 were capable of neutralizing hTNF-α at sub-
nanomolar concentrations (Table 2).
affinity Determination
The equilibrium dissociation constant (KD) for lead VNAR 
domains was determined on the Octet® RED96 system as described 
above. As anticipated, the binding affinity of these multivalent 
domains significantly improved as a result of an enhanced avidity 
effect. The measured KD values were in the sub-nanomolar range 
for the multivalent VNAR constructs, demonstrating a 600-fold 
improvement in affinity following reformatting of parental 
domains (Table 1).
TnF-α neutralization in l929 cell line
Neutralization of hTNF-α-induced cytotoxicity in L929 cells 
remains one of the gold-standard in  vitro efficacy experiments 
for determining the potency and therapeutic potential of anti-
hTNF-α biologics. In this assay, the measured ND50 for the 
unformatted VNAR monomers D1 and C4 was ≈30 and 100 nM, 
respectively (Table 2). The control VHH monomer has an ND50 of 
less than 10 nM in our assay. The ability of the VNAR constructs 
to neutralize the cytotoxic effect of hTNF-α was significantly 
improved in the reformatted constructs from monomer to dimer 
and again to trimer with these trivalent domains showing the 
most enhanced potencies (Table  2). Of particular interest are 
the D1–C4 and D1–BA11–C4 formats. The D1–C4 had an ND50 
value 10-fold better than its counterpart homodimer (D1–D1, 
ND50 7 nM), and D1–BA11–C4 had an ND50 value of only 20 pM 
which is almost 20-fold better than its counterpart D1–BA11–D1 
(Figure  3; Table  2). These consistent and significant improve-
ments seen for the mixed parental dimer clones (with D1 at the 
N-terminal end of the fusion protein) strongly suggest that D1 
and C4 bind unique epitopes on the TNF-α molecule, delivering 
a bi-paratopic fusion protein of improved neutralizing potency.
reformatting Parental Domains as Vnar-
Fc constructs
Multivalent VNAR domains in the size range 25–40 kDa (D1–C4 
and D1–BA11–C4, respectively) with picomolar neutralizing 
potency for hTNF-α were expressed successfully in E. coli. 
Although these small domains are well suited to site-specific 
delivery, they can also be administered systemically because 
they incorporate BA11, a half-life-extending domain (human-
ized VNAR), as part of the spacer region of the fusion protein 
(Figure  2). It is also possible to create fusion proteins that are 
closer to natural antibodies and incorporate an immunoglobulin 
Fc region. By carrying out these simple molecular fusions both 
N and C terminally to the human Fc region of an antibody it has 
been possible to generate the Quad-X™ and Quad-Y™ family 
of proteins both of around 50 kDa (Figure 4). When expressed 
in a mammalian system these proteins naturally and efficiently 
assemble as quadra-valent, bi-specific, and bi-paratopic proteins 
capable of both half-life extension and immune system recruit-
ment. When examined in a “gold-standard” L929 assay the 
Quad™ family have proved to be super-sensitive neutralizers 
with 2–5 pM efficacy (Figure 5B) and significantly (10×) better 
than even the leading clinical anti-hTNF-α antibody adalimumab 
(Humira®). Even the least potent neutralizer amongst the char-
acterized Quad™ constructs (C4–D1–Fc) is twice as potent as 
Humira® (Table 2).
Bivalent D1–Fc and C4–Fc formats show sub-nanomolar 
efficacies (Figure 5A). Interestingly if equimolar dosing of both 
D1–Fc and C4–Fc are mixed together then a significant enhance-
ment of efficacy is seen over the use of D1–Fc or C4–Fc alone 
and provides additional evidence that the two parental VNARs 
are likely binding different epitopes on the hTNF-α molecule 
(Figure 5A).
FigUre 3 | Efficacy assessment in standard L929 cell-based assay. Neutralization of 0.3 ng/ml hTNF-α-induced cytotoxicity in an actinomycin-D primed 
fibrosarcoma cell line (L929). (a) hTNF-α neutralization assay with anti-hTNF-α monomeric constructs at a maximum concentration of 500 nM. Results are the 
mean ± SD (n = 2) with two replicates per experiment. (B) Neutralization with multivalent anti-hTNF-α variable new antigen receptor (VNAR) constructs at maximum 
concentration of 100 nM. Results are the mean ± SEM (n = 3) with two replicates per experiment. Results (B) were analyzed statistically using a two-way ANOVA 
with Bonferroni’s multiple comparison post hoc test. VNAR BA11 was included as a negative control domain in all assays where D1–BA11–D1 and D1–BA11–C4 
were tested.
FigUre 2 | Diagrammatic representation of multivalent anti-hTNF-α variable new antigen receptor (VNAR) constructs. Bivalent constructs contain flexible (Gly4Ser)2 
linkers while their trimeric counterparts in addition to having flexible GlySer linkers incorporate an anti-human serum albumin (HSA) humanized VNAR (soloMER™), 
called BA11 (26, 41). This additional anti-HSA binder acts as a spacer and a half-life extension tool for prolonged systemic bioavailibity of the trivalent VNAR. The 
functional binding of BA11 to HSA was not compromised by the presence, in the expressed fusion protein, of the anti-TNF-α binding VNARs (data not shown).
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assessing efficacy of anti-hTnF-α Vnars 
in an In Vitro Model of epithelial Barrier 
Dysfunction
While the Quad™ family would be suitable for parenteral admin-
istration, it is possible that the smaller dimer and trimer proteins 
may be ideal for topical or localized, site-specific administration 
avoiding the risk of systemic complications. One such clinical 
destination may be the lining of the gut to suppress or down-
regulate debilitating inflammation in conditions such as inflam-
matory bowel disease (IBD). While immunogenicity of VNAR 
domains would not be an important consideration in the intes-
tine, their ability to tolerate and remain functional in this harsh 
environment would of course be vital if any therapeutic benefit 
is to be seen. VNARs are known to exhibit exceptional stability 
in harsh physiological conditions (28–30). Here, we investigated 
if reformatting of the parental VNAR monomers as multivalent 
domains impacted on this characteristic stability. In particular 
these studies focused on low pH 3 stability over extended periods 
of exposure (3–28 days). All formats tested showed an excellent 
tolerance to this extreme of pH even after 28 days with the dimer 
D1–C4 retaining almost full functionality (Table 3).
The utility of the VNAR formats was then tested in a series of 
bio-assays that mimic barrier dysfunction in IBD. Barrier dys-
function can be induced in IFN-γ primed Caco-2 monolayers by 
hTNF-α and results in disruption of tight junction morphology. 
Using the method described in Wang et al. (37), epithelial barrier 
dysfunction was created in vitro by treating fully differentiated 
Caco-2 cells with hTNF-α causing loss in barrier function (meas-
ured as leakage of solutes across tight-junctions and a decline in 
trans-epithelial resistance). The ability of anti-hTNF-α VNAR 
domains to block this dysfunction was assessed by studying 
TaBle 3 | Binding ELISA of variable new antigen receptor (VNAR) constructs 
post 28 days incubation at pH 3.
Binding domain
% retention of binding activity to hTnF-α
ph3
Day 3 Day 7 Day 28
D1 88 ± 10.2 51 ± 1.3 67 ± 3.4
C4 78.3 ± 3.8 85 ± 0.1 78 ± 3.8
TNF30 90 ± 0.4 78 ± 6.6 80 ± 9.7
D1–D1 91.6 ± 0.3 31.6 ± 1.6 49 ± 0.8
D1–C4 122.8 ± 0.3 106 ± 9.5 81 ± 7.4
D1–BA11–D1 97.9 ± 2.3 106 ± 1.6 77.6 ± 0.7
D1–BA11–C4 72 ± 4.2 60 ± 2.0 73.9 ± 3.8
Anti-HSAmAb n/a 36.1 ± 0.1 1.6 (Day 21)
VNAR protein samples incubated at pH 3 for 3–28 days were neutralized in phosphate 
buffered saline, pH 7.4 to a final concentration of 0.5 µg/ml before loading onto a 1 µg/
ml hTNF-α and/or human serum albumin (HSA)-coated ELISA plates. Binding activity 
was measured as percentage residual activity compared to an untreated control at 
each time point. Results shown are the mean ± SD (n = 1 with multiple replicates 
per experiment). The control anti-human serum albumin monoclonal is clone HSA-11 
produced in mouse (Sigma, A6684).
FigUre 5 | hTNF-α neutralizing capacity of the Fc-based variable new antigen receptor (VNAR) constructs. (a) VNAR-Fc constructs demonstrating high 
neutralization potencies. D1–Fc + C4–Fc denotes equimolar dosing of both constructs. Results shown are the mean ± SEM (n = 3) with two replicates per 
experiment. (B) A demonstration of the superior potency of the Quad™ VNAR constructs over Humira® in neutralizing hTNF-α-induced cytotoxicity in L929 cells. 
Results shown are the mean ± SEM (n = 4) with two replicates per experiment (D1–Fc–C4) and mean ± SD (n = 2) with two replicates per experiment for the other 
constructs and Humira®.
FigUre 4 | Diagrammatic representation of variable new antigen receptor (VNAR)-Fc constructs. VNAR-Fc constructs of D1 and C4 were generated by direct 
fusion of VNARs to the hinge of a wild-type human IgG1 Fc. These directly fused VNARs contained a Glycine-rich residue (GGGSGGGGSG) at the end of 
framework 4 region, and it is this glycine-rich residue that is fused to the hinge. Quad-Y™ constructs are fused to the N-terminal position of the human Fc (as 
shown in the diagram). The VNARs in a Quad-Y format are linked by a flexible Gly4Ser linker (GGGGSGGGGSGGGGSGGGGS). The Quad-X™ are VNARs fused 
to both N- and C-terminal ends of the wild-type human IgG1 Fc. The C-terminally fused VNAR is linked to the CH-3 fragment via a flexible Gly4Ser linker (as 
previously described).
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both the: paracellular flux of large molecular weight hydrophilic 
molecules such as FITC-dextran and changes in the TEER of the 
treated Caco-2 cells monolayer. On average the dimer VNAR 
constructs restored TEER in cytokine treated cells to about 
94.4% of the untreated control cells. Interestingly, VNAR D1–C4 
restored TEER in cytokine treated cells to about 104.6 ± 5.34% 
of untreated control and was identical in potency to adalimumab 
(Humira®) which restored TEER to 103.8 ± 12.1% of untreated 
control (Figure 6).
Variable new antigen receptor monomers restored barrier 
integrity on average to 63% of untreated, while the VNAR mul-
tivalent constructs restored integrity to about 73% of untreated 
control (Figure  7). VNAR D1–C4 and VNAR D1–BA11–C4 
restored barrier integrity to about 78 and 84%, respectively, 
while adalimumab at equimolar dose restored epithelial integ-
rity by 83%. These efficacy data clearly indicate that the VNAR 
multivalent constructs are comparable in in vitro efficacy assays. 
The barrier leakage can be detected after 2  h of adding FITC-
dextran in the unprotected or negative control treated cells (BA11 
FigUre 7 | Efficacy of anti-hTNF-α variable new antigen receptors (VNARs) 
in preventing FITC-dextran paracellular flux in Caco-2 cell model of cytokine 
induced intestinal barrier dysfunction. All VNAR monomers were added at a 
final concentration of 50 nM while multivalent domains and adalimumab were 
added at a final concentration of 25 nM. FITC-Dextran flux was measured by 
taking media from the basolateral chamber at 2 h (a) and 24 h (B) 
post-addition of FITC-Dextran (i.e., 20 and 42 h post cytokine ± anti-TNF-
treatment, respectively). Results shown are the mean ± SD (n = 1) with four 
replicates per experiment, and all treatment groups have been corrected for 
the fluorescence intensity measured in untreated cells. y-Axis on both bar 
charts are on different scales. VNAR 2V is an isotype control isolated from a 
naïve library, and has no inherent affinity for any known target antigen (33, 
40). VNAR BA11 has been described elsewhere in this paper.
FigUre 6 | Effect of anti-hTNF-α variable new antigen receptors (VNARs) on 
trans-epithelial resistance disruption in Caco-2 cell model of cytokine-
induced intestinal barrier dysfunction. Monolayer cells were treated with 
10 ng/ml hTNF-α and IFN-γ. All VNAR monomers were added at a final 
concentration of 50 nM while multivalent domains and adalimumab were 
added at a final concentration of 25 nM. Results shown are the mean ± SD 
(n = 1 with ≥8 replicates per experiment). Results were statistically analyzed 
using a one-way ANOVA with Dunnett’s post hoc test [*** where P < 0.0001; 
not significant (ns) where P > 0.05]. VNAR 2V is an isotype control isolated 
from a naïve library, and has no inherent affinity for any known target antigen 
(33, 40). VNAR BA11 has been described elsewhere in this paper.
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treatment), while protection is evident even at 2 h and sustained 
over a 24 h period (Figure 7).
DiscUssiOn
IgNAR V regions (VNAR) have been successfully generated against 
a range of targets from immunized, naïve and semi-synthetic 
display VNAR libraries (16, 22, 23, 26, 31, 42–45). The notion 
that IgNAR are part of the adaptive immune system of sharks has 
been reported previously (16, 26), and although time consuming, 
immunization still remains our preferred route for the isolation of 
high-affinity binders or neutralizers. Shark immunization route 
can be particularly useful for cross-species conserved proteins as 
sharks are evolutionarily distant from humans, diverging from 
a common ancestor approximately 450 million years ago and, 
therefore, the likelihood of immune tolerance to such a protein 
antigen is much less likely (15, 20, 46).
In our pre-selected, but immunized VNAR library, 6% of ran-
domly selected clones were specific to hTNF-α. We also observed a 
post-selection preference for the characteristic CDR3-protruding 
type II VNARs, suggesting that our anti-hTNF-α VNARs may be 
accessing recessed epitopes on the hTNF-α molecule.
Here, we demonstrate extensive multivalent reformatting of 
VNAR fragments, with significant improvement in in vitro effi-
cacy (beyond that of clinical antibodies to the same target) and 
multifunctionality while retaining our unique selling point of 
“small size” (less than 50 kDa) and flexible expressibility. Using 
a human antibody Fc region as a spacer in molecular fusions, 
we have generated for the first time super-potent quadra-valent 
VNAR-Fc constructs, with two main classes named Quad-X™ 
and Quad-Y™ after their shape when drawn in a stylized form 
(Figure  4). The significant improvement in binding affinity 
across the multivalent VNAR constructs (Table 1) is likely to 
be due to avidity effects. A similar stepwise trend was seen in 
all in vitro neutralization experiments, reaching a 50,000-fold 
efficacy improvement when comparing a single monovalent 
VNAR to Quad-X™ in the gold-standard L929 neutralization 
assay.
A number of diseases are associated with alterations in the 
intestinal barrier and its increased permeability. IBD, Irritable 
bowel syndrome, celiac disease, as well as extra-intestinal 
diseases such as type 1 diabetes, acquired immunodeficiency 
syndrome, multiple sclerosis, and rheumatoid arthritis have all 
been linked to intestinal barrier defects (47–51). For IBD patients 
that display increased intestinal paracellular permeability, TNF-
α levels become elevated in the intestinal mucosa, serum, and 
stools of these patients (47), with recent in vitro studies further 
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suggesting that increased TNF-α impairs the intestinal tight 
junction barrier via upregulation of the myosin light-chain 
kinase protein expression (37, 52). Existing clinically available 
anti-TNF therapies (e.g., adalimumab, infliximab, and certoli-
zumab) are an effective therapy for these pateints with remis-
sion seen for Crohn’s disease and other related conditions (53). 
Despite the relative molecular and valency differences between 
the different anti-TNF-α biologic drug classes (95–150  kDa), 
both in  vitro neutralization studies and clinical retrospective 
and non-randomized studies have demonstrated comparative 
efficacy (53–57). However, a common to all approach is a series 
of well documented systemic complications that include: immu-
nogenicity and resulting ADA, profound issues with patient 
compliance because of a repeated injection dosing paradigm 
and serious side-effects associated with prolonged use (risk 
of life-threatening infections and/or lymphomas) (13, 14, 58). 
Therefore, the use of smaller molecular weight anti-TNF-α 
biologics through site-specific delivery may enhance clinical 
outcomes by reducing the level of systemic exposure to these 
powerful and pleiotropic biologic drugs (59, 60).
Intra-gastric delivery of an anti-TNF-α VHH constructs using 
an orally administered engineered Lactococcus lactis (L. lactis) 
significantly reduced inflammation in dextran sulfate sodium-
induced chronic colitis mice (61). This approach effectively 
delivers the single-domain VHH to the colon, thereby limiting 
or circumventing unnecessary exposure of the domain to the 
very acidic pH of the gastric environment and its associated 
gastric enzymes. In a preliminary study, VNAR D1–C4 efficiently 
expressed in L. lactis and neutralized hTNF-α in L929 assay with 
ND50 value of 105 pM.
To partially mimic the effects of site-specific delivery, we 
have utilized an in vitro cell-based intestinal epithelial dysfunc-
tion model, and have shown that even our monovalent VNAR 
domains elicit excellent protection against the inflammatory 
toxicity generated by the presence of human TNF-α. This protec-
tion was improved when the VNARs were used in dimer or trimer 
formats and the level of activity seen was equivalent to that of a 
clinical antibody control, Humira® (Figures  6 and 7). In a pH 
stability test, designed to mimic the environment of the gut, only 
the VNAR and VHH domains retained any activity (around 80%) 
after 7 days exposure (Table 3).
It was originally proposed, that unlike the VHH domains 
(62–64), VNARs might not efficiently form a dimeric fusion 
molecule, and even where dimerization of VNAR was achieved, 
the resulting dimeric construct showed a compromised expres-
sion level and binding activity thought to be due to steric 
hindrance or occlusion of the binding site by the incorporated 
linker (17). It was later shown that VNARs do in fact tolerate 
both N- and C-terminal molecular fusions to form either a 
dimer or trimer construct without significant loss of binding 
characteristics (25). In fact, improvements in binding kinetics, 
efficacy and pharmacokinetics of domains have been achieved 
through reformatting parental VNAR and VHH domains as 
multivalent and/or multi-specific domains (21, 25, 41, 63–66). 
Increasing the valency of binding domains such as from a 
monovalent Fab to a bivalent Fab fragment, monovalent scFv to 
bivalent scFv-Fc, or from a monovalent VHH to a bivalent, or 
trivalent VHH domain have shown in some cases up to a 500-
fold increase in potency and/or affinity for a range of antigens 
and assays. Enhanced avidity and even additional mechanism 
of binding fragment-antigen interactions have been shown to 
be largely responsible for the improved efficacy seen with these 
multivalent binding domains (64, 65, 67). The improvements we 
have seen in potency is greater than one would have expected 
from just avidity (Tables  1 and 2) alone with some domains 
(e.g., D1–BA11–C4, Quad-X™ D1–Fc–C4) showing improve-
ments of over 10,000-fold. As these jumps in potency are always 
associated with combinations of the D1 and C4 domains (and 
in that order), we postulate that some of this enhancement in 
neutralization may be due to bi-paratopic binding, not avid-
ity alone. Further analysis would be required to confirm this 
hypothesis.
Any increase in valency of the VNAR domains increases 
the number of possible epitopes that can be assessed on a 
bioactive hTNF-α trimer, and this capacity has been optimized 
here using an empirically designed flexible linker (Figure  2). 
Previous studies have shown that multivalent constructs 
spaced by a short linker can achieve increased functionality 
by improving their antigen binding through avidity, increased 
antigen specificity or by cross-linking two hTNF-α trimers (64, 
68, 69). We, therefore, hypothesize that the short but flexible 
11 amino acid GlySer linker in the dimeric VNAR constructs 
(D1–C4) allow these domains to interact with two epitopes on 
one trimeric TNF-α molecules and/or cross-link the interaction 
of two epitopes on two trimeric TNF-α molecules. Similarly, 
the trivalent VNAR domains (D1–BA11–C4) were constructed 
with an increased spatial separation of the anti-TNF-α VNAR 
domains using two 20 amino acid flexible GlySer linkers and a 
103 amino acid VNAR BA11 “spacer,” which further enhanced 
the ability (reach) of these constructs to interact and cross-link 
bioactive trimeric TNF-α molecules. The VNAR BA11, is a 
humanized anti-HSA soloMER™ capable of both increasing 
the spatial separation of the anti-hTNF-α VNAR domains and 
providing an option for serum half-life extension if used in a 
systemic, therapeutic setting (25, 41). The logical extension of 
this approach is our Quad-X™ family of proteins (D1–Fc–C4). 
Here, we have replaced the BA11 spacer with a human Fc region 
(half-life extension and immune system recruitment) but have 
enhanced the neutralizing potency of the fusion protein further 
by increasing the valency of both D1 and C4 domains through 
natural and efficient dimerization of the expressed protein. This 
proved to be the most potent of all the constructs tested deliver-
ing complete neutralization at only 2 pM compared to 30 pM by 
the world’s best-selling drug Humira®.
The simple molecular architecture of VNAR domains facili-
tates flexible reformatting options and the accommodation of 
additional functionality to deliver a panel of therapeutically 
useful formats optimized for administration both as systemic 
and/or site-specific drugs. This flexibility can also be used to 
enhance drug potency delivering a new class of biologics that can 
match and even surpass the activity of some of the best studied 
therapeutic antibodies and deliver this enhanced potency with 
easily expressed fusion proteins that are two-third the size of a 
whole antibody.
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eThics sTaTeMenT
This study was conducted in accordance with the recommenda-
tions of HMRC described in the project license—PPL 60/3799. 
Work conducted by the Institute of Marine and Environmental 
Technology (Baltimore, MD, USA) was under their ethical 
guidelines and authorized animal procedures. Sharks were kept 
in an extensive state of the art fish-holding facility as part of an 
environmentally responsible marine core facility that provides 
excellent experimental capacity for research with marine organ-
isms. It is a completely contained, recirculating operation with 
large-scale mechanical and biological filtration and life support 
systems that enable safe and efficient re-use of tank water.
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